Japan Clears Five Products in a Day, Two With a Price Cut Attached
Four companies announced Japanese approvals on 16 September 2026, covering five products. The date was set by the ministry’s calendar rather than by any of the files, and the same calendar now sends all five into one price listing round, where the rules reward launching and penalise growing.
Japan’s Ministry of Health, Labour and Welfare approved Daiichi Sankyo’s Enhertu with pertuzumab for first-line HER2-positive unresectable or recurrent breast cancer, and Datroway for first-line triple-negative disease in patients not eligible for PD-1 or PD-L1 therapy. Daiichi Sankyo commercialises both in Japan itself.
On the same date Lundbeck received authorisation for Vyepti in migraine prevention, Viatris for Wakix in narcolepsy and in excessive daytime sleepiness with obstructive sleep apnoea syndrome, and Eisai and Biogen for Leqembi Pen, a once-weekly subcutaneous autoinjector for early Alzheimer’s disease.
Under MHLW rules, a new drug is listed on the National Health Insurance price list within 60 days of approval in principle and 90 days at the latest. Listings run roughly four times a year, and in practice fall in February, May, August and November.
Japan’s market expansion repricing rules cut prices when sales pass forecast-linked benchmarks. Synopulse reported in August that Dupixent, Nucala and Vyvdura were each cut after a label expansion, and that Datroway faces a reduction of about 11% set by reference to a competitor’s cost-effectiveness assessment.
The approval date came from the calendar, not from the dossiers
Five products from four companies, in oncology, neurology and sleep medicine, cleared on the same day. Nothing about a breast cancer combination, an intravenous migraine antibody and an Alzheimer’s autoinjector makes them ready simultaneously.
Japan approves in batches, and pricing follows on a fixed administrative clock rather than on a negotiation. That combination is what makes the market predictable, and it is the strongest argument Japanese regulators have when companies complain about everything else.
The consequence for competitive tracking is that a Japanese approval date carries less information than a European or American one. It does not tell you the file was strong or the review was fast. It tells you which batch it landed in, and therefore which listing round sets the price. For this cohort that is November.
Enhertu and Datroway moved to first line, which is the event the pricing system punishes
The Enhertu approval rests on DESTINY-Breast09, where the combination with pertuzumab cut the risk of progression or death by 44% against taxane, trastuzumab and pertuzumab, with median progression-free survival of 40.7 months against 26.9. Datroway’s rests on TROPION-Breast02, with a 43% reduction against investigator’s choice of chemotherapy, median PFS of 10.8 months against 5.6, and median overall survival of 23.7 months against 18.7.
Both are strong first-line datasets. Both also move an existing Japanese product from a later line into the largest patient pool in metastatic breast cancer, and volume is precisely the variable Japan reprices on.
The mechanism is documented and Synopulse has covered it: market expansion repricing and the huge seller adjustment cut the price of a drug whose sales pass a benchmark set against a forecast made before the expansion existed. Sanofi’s Dupixent took about 3.7% after adding COPD, GSK’s Nucala about 10% after nasal polyps, Argenx’s Vyvdura about 15% after chronic inflammatory demyelinating polyneuropathy.
Datroway sits in a harder position still. It is already facing a reduction of around 11% under the H5 category, where the price moves by reference to the pricing comparator’s cost-effectiveness result rather than its own. Gilead’s Trodelvy is that comparator. A first-line indication on top of that is volume growth inside a system that has already demonstrated it will move this product’s price on someone else’s evidence.
The safety line that will follow the launchBoth products carry interstitial lung disease warnings in Japan. In DESTINY-Breast09, adjudicated drug-related ILD or pneumonitis was reported in 12.1% of patients on the Enhertu combination against 1.0% on standard therapy, including two grade 5 events, and Daiichi Sankyo’s Japanese approval materials put the rate among Japanese patients in the trial at 33.3%. A first-line label multiplies the number of patients exposed to that risk in the market where the subgroup rate is highest, which makes monitoring capacity, not efficacy, the practical constraint on uptake.
Lundbeck and Viatris bought access to the market, not molecules
Vyepti has been approved in the United States since February 2020 and in Europe since January 2022, and is launched in more than 30 markets. What is new is that this is Lundbeck’s first Japanese launch as marketing authorisation holder, after 25 years of operating in the country through others.
Wakix arrived at Viatris through the October 2025 acquisition of Aculys Pharma, which held the Japanese rights to pitolisant. Eleven months later the company has two approved indications, first-in-class positioning as a histamine H3 antagonist in Japan, orphan designation in narcolepsy, and a product that is not scheduled as a controlled substance in a market where the alternatives are stimulants.
Neither company discovered anything. Both bought a route into a system where the barrier is the licence to operate rather than the compound, and both turned that purchase into a label inside a year. For competitors, the read is that Japanese market entry is now an acquisition decision with a knowable timetable.
Leqembi’s change is a device, and that is the competitive move
Leqembi Pen adds once-weekly subcutaneous dosing at home to an intravenous product given every two weeks in hospital. Nothing about the molecule changed.
In a country where the infusion chair, the neurology appointment and the caregiver’s day are the scarce inputs, the delivery route is the commercial variable. Eisai has moved the treatment out of the hospital in the market with the oldest population and the largest amyloid-eligible cohort. That is a defensive move against every anti-amyloid competitor that still requires an infusion suite.
What to watch
The November NHI listing round, where all five products get their prices. Premiums for novelty and for paediatric or orphan status are decided there, and Wakix’s orphan designation in narcolepsy is the one to watch in this cohort.
The next repricing cycle for Enhertu and Datroway. The FY2026 revision cut prices by an average of about 4% on a spending basis across roughly 15,800 products, and the abolition of the spillover rule removed one route by which a competitor’s volume could pull a price down. The market expansion mechanism itself remains.
Whether Daiichi Sankyo discloses Japanese volumes separately. It holds Japan alone while partnering elsewhere, so Japan is the one market where its own disclosure determines what outsiders can see about the benchmark being approached.
Five approvals in one day looks like momentum. In a system that lists prices on a fixed clock and cuts them when volume grows, it is better read as five companies arriving at the same tollbooth, two of them carrying the load that gets taxed.